

Supplementary Table S1. Work-related patient-reported outcomes at week 24 according to remission status in working patients from RA-BEAM.

PRO Measure	n	Baseline	Mean Value at Week 24	Observed Change at week 24	n	Baseline	Mean Value at Week 24	Observed Change at Week 24	n	Baseline	Mean Value at Week 24	Observed Change at Week 24
Patients in remission on placebo (n = 24)				Patients in remission on baricitinib 4 mg (n = 87)				Patients in remission on adalimumab (n = 57)				
Absenteeism (%)	10	7.1	4.3	-2.8	34	5.2	5.9	0.7	34	4.1	1.5	-2.5
Present at work (%)	10	22.0	11.0	-11.0	34	45.9	9.7	-36.2	34	33.5	11.5	-22.1
Productivity loss (%)	10	24.8	13.1	-11.7	34	47.7	14.1	-33.6	34	35.3	13.0	-22.3
Activity impairment (%)	24	37.5	17.5	-20.0	87	52.1	14.4	-37.7	57	41.2	14.6	-26.7
Patients in remission or low disease activity on placebo (n = 46)				Patients in remission or low disease activity on baricitinib 4 mg (n = 154)				Patients in remission or low disease activity on adalimumab (n = 110)				
Absenteeism (%)	21	3.5	4.4	0.9	66	5.9	6.8	0.9	62	5.9	5.3	-0.5
Present at work (%)	21	33.8	16.2	-17.6	66	43.0	13.2	-29.8	61	37.4	13.8	-23.6
Productivity loss (%)	21	35.2	19.1	-16.1	66	45.6	18.7	-26.9	61	39.7	15.9	-23.8
Activity impairment (%)	46	43.5	20.0	-23.5	154	52.7	15.9	-36.8*	110	47.3	17.0	-30.3
Patients not in remission or low disease activity on placebo (n = 276)				Patients not in remission or low disease activity on baricitinib 4 mg (n = 267) ‡				Patients not in remission or low disease activity on adalimumab (n = 157) ¶				
Absenteeism (%)	111	14.5	11.0	-3.5	94	15.0	9.2	-5.8	48	19.5	10.2	-9.3
Present at work (%)	102	45.4	37.2	-8.2	87	45.5	31.6	-13.9 *	44	54.8	35.9	-18.9 *
Productivity loss (%)	102	48.3	41.3	-7.0	87	48.9	34.6	-14.3 **	44	58.2	39.8	-18.4 *
Activity impairment (%)	276	57.6	42.7	-15.0	266	60.3	36.4	-23.9 ***	156	63.7	40.8	-22.8 *

At baseline, 41–43% of patients from RA-BEAM reported being employed. Remission was defined as DAS28-ESR <2.6 and low disease activity as DAS28-ESR ≥2.6 and ≤3.2. Numbers in bold are significantly different compared with placebo. *BARI* baricitinib, *DAS28-ESR* Disease Activity Score for 28-joint count with erythrocyte sedimentation rate, *MTX* methotrexate, *PRO* patient-reported outcome. ‡One patient was missing from the BARI+MTX group. ¶One patient was missing from the ADA+MTX group. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. place.